Lessli Rushforth
6 Papers
5 Citations
Lessli Rushforth is an academic researcher. The author has contributed to research in topics: Head and neck squamous-cell carcinoma & Cancer. The author has an hindex of 2, co-authored 3 publications.
Chat about Author
Papers
Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
Rom Leidner,Marka R. Crittenden,Kristina H. Young,Hong Xiao,Yaping Wu,Marcus Couey,Ashish A. Patel,Allen C. Cheng,Amber L. Watters,Carlo Bifulco,George Morris,Lessli Rushforth,Shorin Nemeth,Walter J. Urba,Michael J. Gough,R. Bryan Bell +15 more
TL;DR: The Neoadjuvant Immuno-Radiotherapy Trial as mentioned in this paper was an investigator-initiated single institution phase Ib clinical trial that enrolled patients with previously untreated locally advanced head and neck squamous cell carcinoma between 2018 and 2019.
110
Abstract CT182: Neoadjuvant immuno-radiotherapy (NIRT) in head and neck cancer: Phase I/Ib study of combined PD-1/SBRT prior to surgical resection
Rom Leidner,R. Bryan Bell,Kristina H. Young,Brendan D. Curti,Marcus Couey,Ashish Patel,Amber L. Watters,Hong Xiao,Carlo Bifulco,Brian D. Piening,George Morris,Lessli Rushforth,Dawn Brucker,Shorin Nemeth,Michael J. Gough,Marka R. Crittenden +15 more
TL;DR: This study represents a major paradigm shift in the approach to treatment of locally advanced p16+ oropharyngeal cancers with a high response rate and lower toxicity profile, and favors the 8Gy x3 cohort for development.
4
Cohort Expansion Study of Neoadjvuant Immunoradiotherapy in Locoregionally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma
Richard Bryan Bell,Rom Leidner,Kristina H. Young,Brendan D. Curti,Marcus Couey,Ashish Patel,Amber L. Watters,Hong D. Xiao,George Morris,Lessli Rushforth,Michael J. Gough,Marka R. Crittenden +11 more
1
Abstract CT123: Trial in progress: First-in-human immunotherapy-trio for advanced head and neck squamous cell carcinoma
Marcus Couey,Matthew H. Taylor,Tarsem Moudgil,Yoshinobu Koguchi,Tanisha Christie,William L. Redmond,Christopher Paustian,Ryan Meng,Venkatesh Rajamanickam,Lessli Rushforth,Abigail Peterson,Brady Bernard,R. Bryan Bell,Carlo Bifulco,Traci L Hilton,Shawn M. Jensen,Hong-Ming Hu,Brian D. Piening,Walter J. Urba,Bernard A. Fox,Rom Leidner +20 more
TL;DR: Couey et al. as mentioned in this paper proposed an off-the-shelf multivalent autophagosome vaccine, DPV-001, to generate stronger tumor specific CD8 T cell responses.
680 Multi-parametric assessment of the immune response to a trio immunotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma
Christopher Paustian,Tarsem Moudgil,Venkatesh Rajamanickam,Noah Simons,Ryan Meng,Marcus Couey,Matthew H. Taylor,Yoshinobu Koguchi,Anne Stadum,Tanisha Christie,Tyler Hulett,Noriko Iwamoto,Takashi Shimada,Yuriko Minegishi,Quyen Vu,William L Redmond,Lessli Rushforth,Abigail Peterson,Brady Bernard,R. Bryan Bell,Carlo Bifulco,Koji Ueda,Traci L Hilton,Shawn M Jensen,Hong-Ming Hu,Brian Piening,Walter J. Urba,Bernard Fox,Rom Leidner +28 more
- 31 Oct 2023
TL;DR: A phase I clinical trial evaluating the safety and efficacy of a multivalent proteasome-blocked autophagosome vaccine (DPV-001) combined with anti-GITR and anti-PD-1 in patients with recurrent or metastatic head and neck squamous cell carcinoma shows promising immune responses.